Product Information

GABAPENTIN 300 MG CAPSULE is a generic product labeled by Major Pharmaceuticals, priced at $0.0328 per EA under NDC 00904666661. Its NADAC has been published 438 times since Jun 27, 2018.

FDA first approved this application on Dec 17, 2010. Its Orange Book therapeutic-equivalence code is AB — FDA rates it therapeutically equivalent to (substitutable for) its reference product.

GABAPENTIN 300 MG CAPSULE

Gabapentin
$0.0328per EA

Strength

300 mg/1

NDC

00904666661

Classification

Generic

Dosage Form

CAPSULE

Route

ORAL

Effective Date

10/21/2026

Active Ingredients

GABAPENTIN

Approval Type

Generic (ANDA)

FDA Application

ANDA090858

FDA Approved

12/17/2010

TE Code

AB

On Market Since

1/29/2011

Pharmacological Classes

Decreased Central Nervous System Disorganized Electrical Activity

Price Statistics

The NADAC for GABAPENTIN 300 MG CAPSULE has been published 438 times since Jun 27, 2018, and over the history we have for it it has declined 22.3%. The table below summarizes its recorded NADAC range and movement.

Current price$0.0328 per EA
All-time high$0.0601 (Jan 16, 2019)
All-time low$0.0301 (Aug 19, 2026)
52-week high$0.0341
52-week low$0.0301
Median price$0.0456
Average price$0.0449
Largest weekly change-17.0% (Nov 20, 2024)
Weeks tracked438
Tracking sinceJun 27, 2018

Price History

1W

0.0%

1M

+4.5%

3M

+6.7%

6M

+1.1%

1Y

-3.4%

3Y

-19.8%

5Y

-38.8%

All

-22.3%

Generic Alternatives

The matcher finds 16 manufacturers offering a NADAC-published product with this drug's active ingredient and strength in a comparable dosage form (cheapest from each manufacturer, up to 10 shown below). Switching to the cheapest would cut per-unit acquisition cost by roughly 8% at current NADAC. These are candidates to verify clinically, not guaranteed substitutes — see our generic drug prices guide.

Continue researching this drug

Use these direct paths to move from a single NDC into the surrounding market, manufacturer, class, and trend context.

Frequently asked questions

What is the NADAC price of GABAPENTIN 300 MG CAPSULE?

The current National Average Drug Acquisition Cost (NADAC) for GABAPENTIN 300 MG CAPSULE, manufactured by Major Pharmaceuticals, is $0.0328 per EA (NDC 00904666661), effective Nov 11, 2026.

How has the price of GABAPENTIN 300 MG CAPSULE changed over time?

Over the history we have for it, the NADAC for GABAPENTIN 300 MG CAPSULE has declined 22.3%. It has been tracked across 438 weekly CMS publications since Jun 27, 2018.

What are the highest and lowest recorded NADAC prices for GABAPENTIN 300 MG CAPSULE?

Since Jun 27, 2018, the NADAC for GABAPENTIN 300 MG CAPSULE has ranged from a low of $0.0301 (Aug 19, 2026) to a high of $0.0601 (Jan 16, 2019), with a median of $0.0456 per EA.

Are there cheaper alternatives to GABAPENTIN 300 MG CAPSULE?

Yes. 16 manufacturers publish a NADAC-priced product with the same active ingredient and strength in a comparable dosage form. The lowest-priced option, GABAPENTIN 300 MG CAPSULE, is $0.0301 per EA — about 8% below GABAPENTIN 300 MG CAPSULE.

Who manufactures GABAPENTIN 300 MG CAPSULE?

GABAPENTIN 300 MG CAPSULE (NDC 00904666661) is labeled by Major Pharmaceuticals, and CMS classifies it as a generic product.